Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06784336 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Study description expanded, about 38 words
    • Collaborators shortened, about 12 words
    v6
  3. Primary completion date: Nov 2028 to Oct 2028
    • Study completion date: Nov 2029 to Oct 2029
    • Start date changed from estimate of Nov 2025 to Oct 15, 2025
    v5
  4. Start date: Sep 2025 to Nov 2025
    • Primary completion date: Sep 2028 to Nov 2028
    • Study completion date: Sep 2029 to Nov 2029
    v4
  5. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Aug 2028 to Sep 2028
    • Study completion date: Aug 2029 to Sep 2029
    • Start date: Aug 2025 to Sep 2025
    • Site details revised
  6. Start date: Apr 2025 to Aug 2025
    • Primary completion date: Apr 2028 to Aug 2028
    • Study completion date: Apr 2029 to Aug 2029
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.
Trial Details
NCT Number NCT06784336
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Allogeneic Stem Cell Transplant
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov